News
Techniques that cause multipotent adult mesenchymal stem cells (MSCs ... to develop innovative and clinically applicable gene and stem-cell-based approaches to musculoskeletal tissue repair.
A new study in the peer-reviewed journal Stem Cells and Development highlights the potential of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) as a therapeutic strategy for high-dose ...
Kiji Therapeutics engineered MSCs + IL-10 and CXCR4 offer tighter targeting and greater potency for challenging inflammatory diseases.
1 Scientists are exploring substitutes for transplantation, including the use of human pluripotent stem cells ... state a cell is in. This work was recently published in Molecular Systems Biology. 3 A ...
2d
News-Medical.Net on MSNEngineered brain cells offer new hope for treating Alzheimer'sA new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and other neurological disorders, according to University of California, Irvine ...
Mitochondria play a crucial role in acquiring pluripotency and determining cell fate. The mitochondrial unfolded protein ...
A new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and other neurological disorders, according to scientists. By engineering human ...
NeuroNata-R is based on autologous bone marrow-derived mesenchymal ... therapeutic potential of stem cells, who may be considering adding a stem cell therapy and/or a gene therapy to their ...
Dr. Guilak's research team developed circadian-based gene circuits, termed "chronogenetics," that can be programmed into stem ...
Hosted on MSN7mon
Trimetallic-based nanocarriers method shows promise for visualized idiopathic pulmonary fibrosis therapyThe TBNCs exhibit remarkable enzyme-like activity, therapeutic gene loading capacity ... Enzyme-like nanoparticle–engineered mesenchymal stem cell secreting HGF promotes visualized therapy ...
Currently, there are only two cell and gene therapies (CGTs ... was the first adipose tissue-derived mesenchymal stem cell asset to receive approval in the GI market in Japan, 2012.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results